How to Survive FDA's New Inspection and Enforcement Practices

Instructor: Dr. Ludwig Huber
Product ID: 704328
  • Duration: 75 Min

recorded version

1x Person - Unlimited viewing for 6 Months
(For multiple locations contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section

Training CD

One CD is for usage in one location only.
(For multiple locations contact Customer Care)
CD and Ref. material will be shipped within 15 business days

Customer Care

Fax: +1-650-963-2556


Read Frequently Asked Questions

This training program will enumerate the inspection process for API, drug and device manufacturers and summarize recent changes. It will guide attendees on preparing staff for the new FDA inspections and discuss the role of exit meeting to avoid enforcement.

Why Should You Attend:

FDA inspections and enforcement recently have become much more aggressive. E.g., the number of 483s and warning letters has doubled over the last five years and shipment holds and multiple product recalls have been announced even for global players. One company had to pay 500 M$ fine as a result of failed inspections and inspectors ask for details they never did before. For the near future FDA expects multifold increase of inspections through the Generic Drug User Fee Amendments (GDFUFA) that will enable FDA to substantially increase the inspection frequency to every 2 years from currently 6-7 years. In addition, the FDA has just released a new powerful guidance listing a variety of circumstances that can even delay, deny, limit or refuse an FDA inspection overall.

This webinar will help survive the new practices through getting up-to-date expert information on the new inspection practices and for preparing your organization accordingly.

Areas Covered in the Webinar:

  • Inspection process for API, drug and device manufacturers
  • Recent changes: summary and details
  • Going through "Reasons for Delaying or Refusing a Drug Inspection" from the new FDA guide
  • 10 examples of recent observations/deviations that came as a surprise
  • Strategy to respond to the new type of inspections
  • Case study: Going through a typical inspection process
  • Preparing your staff for the new FDA inspections
  • Conducting FDA inspection-like internal audits
  • Tips on how to respond during inspections to avoid inspectional observations
  • The role of the exit meeting to avoid enforcement
  • Developing a corrective action plan with identification of the root cause
  • Developing a detailed preventive action plan to avoid reoccurrence
  • How to use all this information for all national and international inspection


For easy implementation, attendees will receive:

  • 80-Page FDA Inspection Survival Guide
  • Two SOPs:
    • FDA Inspections - Preparation, Conduct, Follow Up
    • Responding to FDA 483 Inspectional Observations to Avoid Warning Letters

Who Will Benefit:

  • QA managers and personnel
  • QC directors and substitutes
  • Operations supervisors and staff
  • Regulatory affairs
  • Internal auditors
  • Training department
  • Documentation department
  • Consultants

Instructor Profile:

Ludwig Huber, Ph.D., is the director of Labcompliance and editor of, the global online resource for validation and compliance. He is the author of the books "Validation and Qualification in Analytical Laboratories" and "Validation of Computerized Analytical and Networked Systems." He has given multiple presentations mainly on GLP/GMP, 21 CFR Part 11 and validation around the world. This includes seminars, workshops and presentations for the US FDA, China CFDA, ISPE, PIC/S and several other national health care agencies.

Follow us :
ComplianceOnline Banking Summit 2016 | Risk Management and Data Security - 80390SEM
21 CFR Part 11 Compliance for SaaS/Cloud Applications - 80202SEM

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

Best Sellers
You Recently Viewed